Press Releases

Amarantus and Brewer Sports Announce #C4CT Summit Morning Keynote Presentation by Congressman Chaka Fattah

MINNEAPOLIS, SAN FRANCISCO and GENEVA, June 25, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced that Congressman Chaka Fattah will be delivering the morning keynote address at the #C4CT Concussion Awareness Summit focused on Traumatic Brain Injury-induced Alzheimer's disease at the United Nations on July 31st, 2014. Congressman Fattah will address the Summit regarding policy initiatives currently underway to improve funding for Brain research.

"It is an honor to take part in next month's Summit and help advance America's commitment to brain research, especially as it relates to traumatic brain injury (TBI). The Fattah Neuroscience Initiative is working to leverage the resources within government, while fostering collaborations and cooperation with partners around the globe, to expand our neuroscience capabilities as we seek cures and treatments for Alzheimer's and other brain disease," Congressman Fattah said. "The #C4CT Summit will be a unique opportunity for stakeholders to engage in a necessary dialogue on how to better understand and address the long-term impacts of TBI."

Congressman Chaka Fattah is serving in his 10th term in the U. S. House of Representatives, where he is a senior member of the House Appropriations Committee and the leading Congressional advocate for neuroscience. In 2011 Fattah created the Fattah Neuroscience Initiative and through his leadership on the Appropriations Committee, directed the Office of Science and Technology Policy (OSTP) to establish an Interagency Working Group on Neuroscience (IWGN). The Fattah Neuroscience Initiative is credited as an impetus for the White House BRAIN initiative and the Congressman has been recognized by President Obama for his leadership on the issues of brain research.

The Fattah Neuroscience Initiative is a non-incremental policy initiative designed to make major progress in understanding the human brain by intensifying, in a collaborative fashion, federal research efforts across brain disease, disorder, injury, cognition and development. The initiative aims to coordinate Federal research across agencies and draw upon public private partnerships and the world of academia. This collaboration is significant both in its interdisciplinary nature and the precedence it stands to set in addressing broad national priorities. Congressman Fattah is also partnering with the American Association for the Advancement of Science (AAAS) to host a series of Congressional briefings educating Members of Congress and their staff about current neuroscience research. Topics presented thus far have included infant brain development, traumatic brain injury, and mental illness in young adults.

To register, become a partner, or for additional information, please visit For further questions, please contact Lindsay Lommel at

For sponsorship information please visit:

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About Brewer Sports International

Brewer Sports International (BSI) is a multi-faceted sports advisory firm within The Brewer Group Companies with a focus on the business of sports, wellness and media for professional athletes, sports agencies, public and private corporations and various partners including international organizations, governments and NGOs. Jack Brewer, five-year National Football League (NFL) veteran and former three-team captain, launched BSI in Minneapolis and expanded to New York, Dallas, Miami, Beijing and Malawi. BSI offers a unique financial services platform to professional athletes and sports agencies, as well as high-net-worth individuals and businesses related to professional sports. BSI takes pride in enabling its clients to capitalize on the endless opportunities presented through sport. For more information, please visit or follow them on Facebook, Twitter and LinkedIn.

About #C4CT

The Coalition for Concussion Treatment (#C4CT) was founded in 2012 by former NFL player Jack Brewer, CEO of Brewer Sports International and Gerald Commissiong, President and CEO at Amarantus BioScience Holdings, Inc. with the goal of bringing together those who are directly affected by TBI-induced neurodegenerative diseases with world class researchers, scientists and industry leaders whom are actively working towards identifying and developing innovative TBI treatment opportunities. #C4CT serves as a platform to spread awareness about concussions and the severe effects of Traumatic Brain Injury (TBI). Through a global campaign uniting people who are passionate about the cause, #C4CT fosters the critical discussions and partnerships needed to enhance research, treatment efforts and prevention.

CONTACT: Amarantus Bioscience Holdings, Inc.:
         Aimee Boutcher, Investor Relations
         408.737.2734 x 101

         Brewer Sports International:
         Kristi Hofacker, Interactive Marketing and Media Manager

Amarantus BioScience Holdings, Inc. Logo

Source: Amarantus BioScience Holdings, Inc.